PubHawk
Nat Med March 2022 PMID 35228754

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial.

Adriaan A Voors, Christiane E Angermann, John R Teerlink, Sean P Collins, Mikhail Kosiborod, Jan Biegus, João Pedro Ferreira, Michael E Nassif, Mitchell A Psotka, Jasper Tromp, C Jan Willem Borleffs, Changsheng Ma, Joseph Comin-Colet, Michael Fu, Stefan P Janssens

Download social card

Mentions

243
Peak: 85 in Mar 2022
across 6 sources since Feb 2022

Extended reach

587,842
potential audience

Total likes

555

Video views

9,269

Mentions per month

Feb 2022 – Mar 2025

Where it's discussed

  • X / Twitter211 posts
  • News18 articles
  • Facebook6 posts
  • Blogs4 articles
  • YouTube3 videos
  • Bluesky1 posts

AI synopsis

What people are saying

The discussions demonstrate strong support for the research findings, with posts emphasizing the clinical benefits and safety of empagliflozin, such as 'significant clinical benefit in 90 days,' and use of words like 'well tolerated' and 'significant impact.' The tone and depth of analysis indicate high engagement and recognition of the study’s potential to influence treatment protocols, confirming high interest and impact scores.

AgreementModerate agreement

Most discussion emphasizes the positive outcomes and safety of empagliflozin in acute heart failure, indicating strong support.

InterestHigh interest

The discussions are highly focused on new research findings and their clinical implications, reflecting high interest.

EngagementHigh engagement

Several discussions delve into detailed trial results, statistical analyses, and implications, showing deep engagement.

ImpactHigh impact

Multiple posts highlight that the study provides significant evidence for changing clinical practice and advancing understanding in the field.

Abstract in brief

  • The study tested whether empagliflozin, a drug known to help with chronic heart failure, also provides benefits when given to patients hospitalized for acute heart failure.
  • Patients who received empagliflozin had better clinical outcomes, including fewer deaths and heart failure events, compared to those on placebo, regardless of type of heart failure or diabetes status.
  • The medication was safe and well tolerated, with serious side effects occurring less frequently than in the placebo group, suggesting that initiating empagliflozin during hospitalization for acute heart failure is both effective and safe.]
Read the full abstract

Top posts

Most liked on X and Bluesky
Mauricio Ambriz
@AmbrizMau · X

Los hallazgos de este estudio aleatorizado indican que el inicio de EMPAGLIFLOZINA en hospitalizados por insuficiencia cardíaca aguda, es bien tolerado y produce beneficio clínico significativo en los 90 días posteriores a su inicio. Nat Med 2022; DOI: https://t.co/eNbYM9E2rq https://t.co/IgYNhFqMqc

Oct 14, 2023 · 91 likes · 15 shares · 71,347 followers View post →
Nicolas Manito
@Dr_Manito · X

Just published the EMPULSE trial: The SGLT2 inhibitor empagliflozin, in patients hospitalized for acute heart failure (AHF) is well tolerated and results in significant clinical benefit in the 90 days after starting treatment. New evidence for optimization in AHF setting https://t.co/MnQNjZYbDa

Feb 28, 2022 · 75 likes · 23 shares · 5,471 followers View post →
Mauricio Ambriz
@AmbrizMau · X

Hallazgos de este estudio aleatorizado indican que el inicio de EMPAGLIFLOZINA en hospitalizados por insuficiencia cardíaca aguda es bien tolerado y resulta en beneficio clínico significativo durante los 90 días posteriores a su inicio. Nat Med 2022; DOI: https://t.co/eNbYM9EAgY https://t.co/e1Pec0jxWG

Jan 14, 2025 · 61 likes · 16 shares · 71,347 followers View post →
Francesc Formiga
@FormigaFrancesc · X

GREAT: The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial https://t.co/xNz90Jr8Ik @GiuseppeGalati_ @almucastro01 @SeguraCardio @Dr_Manito @JTLLERGO @fikkumamoto @SABOURETCardio @redGDPS @Diabetes_SEMI @dr_guevara

Feb 28, 2022 · 27 likes · 3 shares · 1,944 followers View post →
Dr Jorge Rico Fontalvo. MD.FISN. FSLANH , PhD
@jorgericof · X

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial | Nature Medicine https://t.co/N6lq4z1gzT

Feb 28, 2022 · 26 likes · 5 shares · 5,113 followers View post →
Jan Biegus
@JanBiegus · X

I am so happy to share our paper showing the clinical benefit of Empagliflozin in acute heart failure settings. EMPULSE trial results. https://t.co/oQtjONfGgk https://t.co/8qzLxf7C3w

Feb 28, 2022 · 24 likes · 5 shares · 436 followers View post →

All mentions

Leonard LN
@leonard49411022 · X

RT @AmbrizMau: Hallazgos de este estudio aleatorizado indican que el inicio de EMPAGLIFLOZINA en hospitalizados por insuficiencia cardíaca…

Mar 26, 2025 · 16 shares · 238 followers View post →
Estefanía Argüello
@tefitasaloata · X

RT @AmbrizMau: Hallazgos de este estudio aleatorizado indican que el inicio de EMPAGLIFLOZINA en hospitalizados por insuficiencia cardíaca…

Jan 16, 2025 · 16 shares · 15 followers View post →
Augusto Rojas Carrión
@AugustoR04 · X

RT @AmbrizMau: Hallazgos de este estudio aleatorizado indican que el inicio de EMPAGLIFLOZINA en hospitalizados por insuficiencia cardíaca…

Jan 16, 2025 · 16 shares · 329 followers View post →
César Corchado
@Kaisar_Cor · X

RT @AmbrizMau: Hallazgos de este estudio aleatorizado indican que el inicio de EMPAGLIFLOZINA en hospitalizados por insuficiencia cardíaca…

Jan 15, 2025 · 16 shares · 275 followers View post →
Marcelo
@imarccelo · X

RT @AmbrizMau: Hallazgos de este estudio aleatorizado indican que el inicio de EMPAGLIFLOZINA en hospitalizados por insuficiencia cardíaca…

Jan 15, 2025 · 16 shares · 95 followers View post →
Dr. Joshuan J. Barboza
@joshuanbarbozam · X

RT @AmbrizMau: Hallazgos de este estudio aleatorizado indican que el inicio de EMPAGLIFLOZINA en hospitalizados por insuficiencia cardíaca…

Jan 15, 2025 · 16 shares · 10,034 followers View post →
Adenosina
@Adenosina11 · X

RT @AmbrizMau: Hallazgos de este estudio aleatorizado indican que el inicio de EMPAGLIFLOZINA en hospitalizados por insuficiencia cardíaca…

Jan 15, 2025 · 16 shares · 4,703 followers View post →
Sebastián Tenorio Vargas
@SebasTenorio · X

RT @AmbrizMau: Hallazgos de este estudio aleatorizado indican que el inicio de EMPAGLIFLOZINA en hospitalizados por insuficiencia cardíaca…

Jan 15, 2025 · 16 shares · 539 followers View post →
Dr. Ronald Caraballo NEFROLOGO
@ronald_nefro · X

RT @AmbrizMau: Hallazgos de este estudio aleatorizado indican que el inicio de EMPAGLIFLOZINA en hospitalizados por insuficiencia cardíaca…

Jan 15, 2025 · 16 shares · 663 followers View post →
Roberto Gutiérrez
@DrRobertoGuti · X

RT @AmbrizMau: Hallazgos de este estudio aleatorizado indican que el inicio de EMPAGLIFLOZINA en hospitalizados por insuficiencia cardíaca…

Jan 15, 2025 · 16 shares · 782 followers View post →
Yvan Espejo
@YvanEspejoA · X

RT @AmbrizMau: Hallazgos de este estudio aleatorizado indican que el inicio de EMPAGLIFLOZINA en hospitalizados por insuficiencia cardíaca…

Jan 14, 2025 · 16 shares · 270 followers View post →
Elizabeth Ferraro
@buguitabuguita · X

RT @AmbrizMau: Hallazgos de este estudio aleatorizado indican que el inicio de EMPAGLIFLOZINA en hospitalizados por insuficiencia cardíaca…

Jan 14, 2025 · 16 shares · 10,755 followers View post →
Gabo Tapia
@alfaunoatsan · X

RT @AmbrizMau: Hallazgos de este estudio aleatorizado indican que el inicio de EMPAGLIFLOZINA en hospitalizados por insuficiencia cardíaca…

Jan 14, 2025 · 16 shares · 188 followers View post →
Mauricio Ambriz
@AmbrizMau · X

Hallazgos de este estudio aleatorizado indican que el inicio de EMPAGLIFLOZINA en hospitalizados por insuficiencia cardíaca aguda es bien tolerado y resulta en beneficio clínico significativo durante los 90 días posteriores a su inicio. Nat Med 2022; DOI: https://t.co/eNbYM9EAgY https://t.co/e1Pec0jxWG

Jan 14, 2025 · 61 likes · 16 shares · 71,347 followers View post →
rmohty
@rmohty · X

@ThachLonnie @markfahlen I've seen a lot of hesitance for "euglycemic DKA" which I think is way overblown... even the actual RCT for acuteHF/inpatient start didn't have any DKA in both arms... https://t.co/867KFMFJdi

Aug 11, 2024 · 611 followers View post →
Lyzinhawer Alza
@LyzinhawerA · X

RT @gunnar_heine: Which second diuretic agent in HF as combination partner with loop diuretics (if any)? After ADVOR by @WilfriedMullens (h…

May 11, 2024 · 4 shares · 22 followers View post →
Михаил
@DoctorMichael81 · X

RT @gunnar_heine: Which second diuretic agent in HF as combination partner with loop diuretics (if any)? After ADVOR by @WilfriedMullens (h…

May 11, 2024 · 4 shares · 18 followers View post →
Oren Caspi
@MDCaspi · X

RT @gunnar_heine: Which second diuretic agent in HF as combination partner with loop diuretics (if any)? After ADVOR by @WilfriedMullens (h…

May 11, 2024 · 4 shares · 3,230 followers View post →
Luis Beck da Silva MD ScD FESC
@luisbeckdasilva · X

RT @gunnar_heine: Which second diuretic agent in HF as combination partner with loop diuretics (if any)? After ADVOR by @WilfriedMullens (h…

May 11, 2024 · 4 shares · 245 followers View post →
Gunnar Henrik Heine
@gunnar_heine · X

Which second diuretic agent in HF as combination partner with loop diuretics (if any)? After ADVOR by @WilfriedMullens (https://t.co/JOxXNVI6bE) & reBEC + CHLOROTIC by @luisbeckdasilva & @jc_trullas (https://t.co/05Qdao5zim), here comes DEA-HF by @MDCaspi https://t.co/rfo1o5l7ir

May 11, 2024 · 10 likes · 4 shares · 2,334 followers View post →
Fundación Cardioinfantil - LaCardio
@fcardioinfantil · X

En nuestro #BlogDeFellows de hoy, hablaremos sobre "El inhibidor de SGLT2 empagliflozina en pacientes hospitalizados por insuficiencia cardíaca aguda: un ensayo aleatorizado multinacional". Encuéntralo completo aquí: https://t.co/KspR4AdI8E #Educación #Ciencia #Cardiología

Mar 27, 2024 · 19,628 followers View post →
Gala ♡♚
@trancelectronic · X

RT @AmbrizMau: Los hallazgos de este estudio aleatorizado indican que el inicio de EMPAGLIFLOZINA en hospitalizados por insuficiencia cardí…

Oct 17, 2023 · 15 shares · 691 followers View post →
Rodrigo Rosillo
@RodrigoRosillo1 · X

RT @AmbrizMau: Los hallazgos de este estudio aleatorizado indican que el inicio de EMPAGLIFLOZINA en hospitalizados por insuficiencia cardí…

Oct 17, 2023 · 15 shares · 75 followers View post →
Juan Luis
@luisfmor · X

RT @AmbrizMau: Los hallazgos de este estudio aleatorizado indican que el inicio de EMPAGLIFLOZINA en hospitalizados por insuficiencia cardí…

Oct 15, 2023 · 15 shares · 105 followers View post →
Roberto Gutiérrez
@DrRobertoGuti · X

RT @AmbrizMau: Los hallazgos de este estudio aleatorizado indican que el inicio de EMPAGLIFLOZINA en hospitalizados por insuficiencia cardí…

Oct 15, 2023 · 15 shares · 782 followers View post →
medicoglia
@medicoglia · X

RT @AmbrizMau: Los hallazgos de este estudio aleatorizado indican que el inicio de EMPAGLIFLOZINA en hospitalizados por insuficiencia cardí…

Oct 15, 2023 · 15 shares · 70 followers View post →
HUGO COLOMBO MD
@HCOLOMBO1958 · X

RT @AmbrizMau: Los hallazgos de este estudio aleatorizado indican que el inicio de EMPAGLIFLOZINA en hospitalizados por insuficiencia cardí…

Oct 15, 2023 · 15 shares · 1,122 followers View post →
Miss Honolulu
@FannySweet23 · X

RT @AmbrizMau: Los hallazgos de este estudio aleatorizado indican que el inicio de EMPAGLIFLOZINA en hospitalizados por insuficiencia cardí…

Oct 15, 2023 · 15 shares · 442 followers View post →
M1A9C8S8$$
@soyelsolis17 · X

RT @AmbrizMau: Los hallazgos de este estudio aleatorizado indican que el inicio de EMPAGLIFLOZINA en hospitalizados por insuficiencia cardí…

Oct 15, 2023 · 15 shares · 42 followers View post →
oe
@edwinle65615556 · X

RT @AmbrizMau: Los hallazgos de este estudio aleatorizado indican que el inicio de EMPAGLIFLOZINA en hospitalizados por insuficiencia cardí…

Oct 15, 2023 · 15 shares · 17 followers View post →
ISLAND MED
@ISLANDMEDCLINIC · X

RT @AmbrizMau: Los hallazgos de este estudio aleatorizado indican que el inicio de EMPAGLIFLOZINA en hospitalizados por insuficiencia cardí…

Oct 14, 2023 · 15 shares · 187 followers View post →
Sebastián Tenorio Vargas
@SebasTenorio · X

RT @AmbrizMau: Los hallazgos de este estudio aleatorizado indican que el inicio de EMPAGLIFLOZINA en hospitalizados por insuficiencia cardí…

Oct 14, 2023 · 15 shares · 539 followers View post →
Edgardo González Rivera
@edgr1972 · X

RT @AmbrizMau: Los hallazgos de este estudio aleatorizado indican que el inicio de EMPAGLIFLOZINA en hospitalizados por insuficiencia cardí…

Oct 14, 2023 · 15 shares · 1,247 followers View post →
Martin Vila
@martinvilagrand · X

RT @AmbrizMau: Los hallazgos de este estudio aleatorizado indican que el inicio de EMPAGLIFLOZINA en hospitalizados por insuficiencia cardí…

Oct 14, 2023 · 15 shares · 5 followers View post →
Mauricio Ambriz
@AmbrizMau · X

Los hallazgos de este estudio aleatorizado indican que el inicio de EMPAGLIFLOZINA en hospitalizados por insuficiencia cardíaca aguda, es bien tolerado y produce beneficio clínico significativo en los 90 días posteriores a su inicio. Nat Med 2022; DOI: https://t.co/eNbYM9E2rq https://t.co/IgYNhFqMqc

Oct 14, 2023 · 91 likes · 15 shares · 71,347 followers View post →
Timoor Mostafa
@TimoorMostafa · X

RT @AbbateAntonio: The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial | N…

Jul 19, 2023 · 7 shares · 217 followers View post →
Aaron Schatz
@Schatz_Aa · X

RT @AbbateAntonio: The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial | N…

Jul 19, 2023 · 7 shares · 333 followers View post →
Lanzule, Inc.
@lanzule · X

RT @AbbateAntonio: The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial | N…

Jul 19, 2023 · 7 shares · 1,054 followers View post →
Natsir Ramadhan
@natsiradhan · X

RT @AbbateAntonio: The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial | N…

Jul 19, 2023 · 7 shares · 557 followers View post →
lal0155
@lal0155 · X

RT @AbbateAntonio: The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial | N…

Jul 19, 2023 · 7 shares · 11 followers View post →
Giuseppe Biondi-Zoccai
@gbiondizoccai · X

RT @AbbateAntonio: The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial | N…

Jul 19, 2023 · 7 shares · 12,112 followers View post →
Aldo Bonaventura
@aldobonaventura · X

RT @AbbateAntonio: The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial | N…

Jul 19, 2023 · 7 shares · 605 followers View post →
AntonioAbbate
@AbbateAntonio · X

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial | Nature Medicine https://t.co/GjcL8HOyPx

Jul 18, 2023 · 20 likes · 7 shares · 1,650 followers View post →
Luis Beck da Silva MD ScD FESC
@luisbeckdasilva · X

RT @gunnar_heine: HCT in HF - here comes the Evidence from @luisbeckdasilva and @jc_trullas https://t.co/pN1UC2v522 via @YouTube. With @Mar…

Apr 28, 2023 · 3 shares · 245 followers View post →
Joan Carles Trullàs, MD, PhD
@jc_trullas · X

RT @gunnar_heine: HCT in HF - here comes the Evidence from @luisbeckdasilva and @jc_trullas https://t.co/pN1UC2v522 via @YouTube. With @Mar…

Apr 28, 2023 · 3 shares · 1,707 followers View post →
marcus_saemann
@MarcusSaemann · X

RT @gunnar_heine: HCT in HF - here comes the Evidence from @luisbeckdasilva and @jc_trullas https://t.co/pN1UC2v522 via @YouTube. With @Mar…

Apr 28, 2023 · 3 shares · 678 followers View post →
Gunnar Henrik Heine
@gunnar_heine · X

HCT in HF - here comes the Evidence from @luisbeckdasilva and @jc_trullas https://t.co/pN1UC2v522 via @YouTube. With @MarcusSaemann @oegnephro @dgfn_ev @com_SFNDT

Apr 28, 2023 · 3 likes · 3 shares · 2,334 followers View post →
Luis Beck da Silva MD ScD FESC
@luisbeckdasilva · X

RT @gunnar_heine: Two studies - One Message: Thiazide Diuretics are of Importance in Decompensated Heart Failure @luisbeckdasilva @jc_trul…

Apr 27, 2023 · 4 shares · 245 followers View post →
Francesc Formiga
@FormigaFrancesc · X

RT @gunnar_heine: Two studies - One Message: Thiazide Diuretics are of Importance in Decompensated Heart Failure @luisbeckdasilva @jc_trul…

Apr 27, 2023 · 4 shares · 1,940 followers View post →
marcus_saemann
@MarcusSaemann · X

RT @gunnar_heine: Two studies - One Message: Thiazide Diuretics are of Importance in Decompensated Heart Failure @luisbeckdasilva @jc_trul…

Apr 27, 2023 · 4 shares · 678 followers View post →
Joan Carles Trullàs, MD, PhD
@jc_trullas · X

RT @gunnar_heine: Two studies - One Message: Thiazide Diuretics are of Importance in Decompensated Heart Failure @luisbeckdasilva @jc_trul…

Apr 27, 2023 · 4 shares · 1,707 followers View post →
Gunnar Henrik Heine
@gunnar_heine · X

Two studies - One Message: Thiazide Diuretics are of Importance in Decompensated Heart Failure @luisbeckdasilva @jc_trullas @MarcusSaemann with @com_SFNDT @oegnephro @dgfn_ev Tomorrow 7:15 PM CEST 2:15 PM Porto Alegre (and later on demand) https://t.co/pN1UC2v522 via @YouTube

Apr 27, 2023 · 5 likes · 4 shares · 2,334 followers View post →
Joan Carles Trullàs, MD, PhD
@jc_trullas · X

RT @luisbeckdasilva: Honoured to discuss Thiazide diuretics in Decompensated Heart Failure with Dr Trullas, author of Clorotic Trial. ⁦⁦@jc…

Mar 31, 2023 · 1 share · 1,707 followers View post →
Luis Beck da Silva MD ScD FESC
@luisbeckdasilva · X

Honoured to discuss Thiazide diuretics in Decompensated Heart Failure with Dr Trullas, author of Clorotic Trial. ⁦⁦@jc_trullas⁩ ⁦@gunnar_heine⁩ #heartfailure https://t.co/Q4O0Xk0PsI

Mar 31, 2023 · 7 likes · 1 share · 245 followers View post →
Das
@ssdas29 · X

@AlanYuNeph have you considered sglt2i ? The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial https://t.co/rIDiAyHXCI https://t.co/OZQZSRBD5a

Jan 24, 2023 · 398 followers View post →
Das
@shivadas29 · X

@AlanYuNeph have you considered sglt2i ? The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial https://t.co/rIDiAyHXCI https://t.co/OZQZSRBD5a

Jan 24, 2023 · 388 followers View post →
Gaby Bautista
@Bautist85573699 · X

RT @JonathanNefro: Iniciar iSGLT2 durante la hospitalización de falla cardíaca agudizada, fue seguro e inclusive ofreció mejoría clínica ⇧3…

Jan 11, 2023 · 54 shares · 235 followers View post →
Dr Imran Sheikh
@DrImranSheikh · X

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial https://t.co/hkCqAUP5ba https://t.co/RDZjif9zDh

Dec 27, 2022 · 24,219 followers View post →
Anace Pastor ✨️ Renalis
@anace710 · X

RT @gudnephron: The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial | Natu…

Nov 3, 2022 · 2 shares · 1,901 followers View post →
Pablo Angeles Tacchino
@pabloange · X

RT @gudnephron: The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial | Natu…

Nov 3, 2022 · 2 shares · 754 followers View post →
Prakash (Pra…Cash) Gudsoorkar (Good..Soor..Kar)
@gudnephron · X

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial | Nature Medicine ⁦@RangaswJ⁩ quotes this paper in her talk. ⁦@ASNKidney⁩ #KidneyWk https://t.co/X5dud24WAL

Nov 3, 2022 · 4 likes · 2 shares · 1,712 followers View post →
Prakash Gudsoorkar
@gudnephron.bsky.social · Bluesky

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial | Nature Medicine ⁦@RangaswJ⁩ quotes this paper in her talk. ⁦@ASNKidney⁩ #KidneyWk https://www.nature.com/articles/s41591-021-01659-1

Nov 3, 2022 View post →
Daniel Martínez
@DanielMtz1896 · X

Artículo original: https://t.co/pQTDuhFD07 Análisis post hoc: https://t.co/w0eaSpiDYb

Oct 23, 2022 · 2 likes · 184 followers View post →
Miguel Turégano
@tureyedro · X

RT @redGDPS: Bibliografia en @PubMedOnline The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinati…

Oct 2, 2022 · 1 share · 813 followers View post →
redGDPS Diabetes
@redGDPS · X

y en @NLM_NIH The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial ... https://t.co/yYQnpoPaUW

Oct 2, 2022 · 3 likes · 15,485 followers View post →
redGDPS Diabetes
@redGDPS · X

Bibliografia en @PubMedOnline The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial https://t.co/gX6jp4DFz5

Oct 2, 2022 · 5 likes · 1 share · 15,485 followers View post →
Syed Shahrul Naz
@drshahrul80 · X

RT @captainchloride: What about the OTHER prox tubule inhibitors #flozins? Esp. relevant in light of EMPULSE showing benefit in starting e…

Sep 20, 2022 · 1 share · 6,926 followers View post →
Nayan Arora,MD
@captainchloride · X

What about the OTHER prox tubule inhibitors #flozins? Esp. relevant in light of EMPULSE showing benefit in starting empa in-hospital https://t.co/OtFE7GGITf

Sep 20, 2022 · 9 likes · 1 share · 3,407 followers View post →
بدر عوض الخرينج
@galkabador · X

RT @ph_adnan: The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial | Nature…

Jul 10, 2022 · 1 share · 901 followers View post →
Adnan Hajjiah
@ph_adnan · X

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial | Nature Medicine #EMPULSEtrial https://t.co/VkVMFSCHFh

Jul 10, 2022 · 3 likes · 1 share · 2,104 followers View post →
Angela Roa
@angelamroab · X

De destacar, que el beneficio de la empaglifozina se observó INDEPENDIENTE de la función ventricular, el estado de diabetes y el deterioro sintomático al inicio del estudio. NATURE MEdiCiNE | VOL 28 | MArch 2022 | https://t.co/bXrLd23OW2

Jun 25, 2022 · 1 like · 1,617 followers View post →
Alfonso Valle
@ValleAlfonso · X

RT @cardiomet_CE: 29b) We also have clinical benefit shown with #empagliflozin in the #EMPULSE study,

Jun 16, 2022 · 2 shares · 21,672 followers View post →
cardio-met
@cardiomet_CE · X

29b) We also have clinical benefit shown with #empagliflozin in the #EMPULSE study,

Jun 16, 2022 · 3 likes · 2 shares · 4,157 followers View post →
Kenichi TSUJITA, MD, PhD, FACC, FESC, FAPSC, FJCS
@KenichiTsujita · X

RT @TomohiroFujisa2: Empulse The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomiz…

Jun 9, 2022 · 1 share · 142 followers View post →
Tomohiro Fujisaki
@TomohiroFujisa2 · X

Empulse The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial | Nature Medicine https://t.co/J8D2qburkA

Jun 4, 2022 · 1 share · 653 followers View post →
Dra.Felix (toxfacts)
@nanibenshorts · X

RT @AdriaanVoors: The EMPULSE main paper is now published online! EMPULSE shows a clinical benefit of the SGLT2 inhibitor empagliflozin in…

Jun 3, 2022 · 134 shares · 126 followers View post →
René Puerto
@renepuerto7 · X

RT @JonathanNefro: Iniciar iSGLT2 durante la hospitalización de falla cardíaca agudizada, fue seguro e inclusive ofreció mejoría clínica ⇧3…

Jun 2, 2022 · 54 shares · 1,373 followers View post →
CVCSCCM
@CVCSCCM · X

The primary outcome was evaluated in the intention-to-treat population through a stratified win ratio approach that is detailed in supplement 1: https://t.co/oFYk4hfqAC #cvcsccmjc

May 25, 2022 · 2 likes · 538 followers View post →
Antonio García
@Volknergarcia · X

RT @javier20ch: Conclusiones: bolo o infusión da igual, dosis altas es mejor (>2.5), inicio temprano del tratamiento (<60 min) y UF como úl…

May 22, 2022 · 1 share · 10 followers View post →
Dr. FEVI
@javier20ch · X

Conclusiones: bolo o infusión da igual, dosis altas es mejor (>2.5), inicio temprano del tratamiento (<60 min) y UF como última opción.

May 21, 2022 · 2 likes · 1 share · 13,375 followers View post →
AcademicCME
@academiccme · X

RT @cardiomet_CE: 30) #EMPULSE, presented at last #AHA21, was the first large RCT dedicated to #SGLT2i in #AHF irrespective of #T2DM status…

May 19, 2022 · 4 shares · 648 followers View post →
Manuel Gaxiola
@cardiogax · X

RT @cardiomet_CE: 30) #EMPULSE, presented at last #AHA21, was the first large RCT dedicated to #SGLT2i in #AHF irrespective of #T2DM status…

May 18, 2022 · 4 shares · 7,977 followers View post →
Giuseppe Galati
@GiuseppeGalati_ · X

RT @cardiomet_CE: 32) #EMPULSE reduced the Primary #EP a composite of: #All_cause_Death, #HFEvent frequency, #Time to first #HFE, #KCCQ_TTS…

May 18, 2022 · 1 share · 10,455 followers View post →
Giuseppe Galati
@GiuseppeGalati_ · X

RT @cardiomet_CE: 30) #EMPULSE, presented at last #AHA21, was the first large RCT dedicated to #SGLT2i in #AHF irrespective of #T2DM status…

May 18, 2022 · 4 shares · 10,455 followers View post →
| Daniel Sierra LM |
@DanielSierraLM · X

RT @cardiomet_CE: 30) #EMPULSE, presented at last #AHA21, was the first large RCT dedicated to #SGLT2i in #AHF irrespective of #T2DM status…

May 18, 2022 · 4 shares · 2,496 followers View post →
cardio-met
@cardiomet_CE · X

30) #EMPULSE, presented at last #AHA21, was the first large RCT dedicated to #SGLT2i in #AHF irrespective of #T2DM status. Here you can see the trial design: any #LVEF, high level of #NT-proBNP_BNP, randomization between 24h and 5d after #HHF See

May 18, 2022 · 14 likes · 4 shares · 4,157 followers View post →
Dr. FEVI
@javier20ch · X

EMPULSE: Empagliflozina en insuficiencia cardiaca aguda.

May 16, 2022 · 3 likes · 13,375 followers View post →
Yasutaka Tsujimoto
@YasutakaTsujimo · X

急性心不全とSGLT2阻害薬　https://t.co/6lmUWQWj8i

Apr 24, 2022 · 47 followers View post →
Lucio
@LucioFlores_ · X

RT @CONAREC_ORG: Tercer Journal del año a cargo del Doctor Flores Lucio @LucioFlores_ _ Residente de segundo año de cardiología. Sanatorio…

Apr 15, 2022 · 3 shares · 823 followers View post →
Facundo Balsano
@fbalsanoMD · X

RT @CONAREC_ORG: Tercer Journal del año a cargo del Doctor Flores Lucio @LucioFlores_ _ Residente de segundo año de cardiología. Sanatorio…

Apr 15, 2022 · 3 shares · 318 followers View post →
Lucas
@lucascampanaok · X

RT @CONAREC_ORG: Tercer Journal del año a cargo del Doctor Flores Lucio @LucioFlores_ _ Residente de segundo año de cardiología. Sanatorio…

Apr 15, 2022 · 3 shares · 855 followers View post →
CONAREC
@CONAREC_ORG · X

Tercer Journal del año a cargo del Doctor Flores Lucio @LucioFlores_ _ Residente de segundo año de cardiología. Sanatorio del Salvador. Córdoba. https://t.co/I6WhNIOsaE #conarec #journal #trial #cardiologia #cardiovascular #residentes #residenteacardiologia

Apr 15, 2022 · 8 likes · 3 shares · 4,965 followers View post →
Msc. Pedro Aguiar
@cardioaguiar · X

RT @AdriaanVoors: The EMPULSE main paper is now published online! EMPULSE shows a clinical benefit of the SGLT2 inhibitor empagliflozin in…

Apr 3, 2022 · 134 shares · 3,099 followers View post →
Hassan Aziz, MD, FACS
@Sharpknife_Aziz · X

RT @jeanfrancis72: The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial | N…

Mar 31, 2022 · 1 share · 3,938 followers View post →
Jean francis MD,FASN
@jeanfrancis72 · X

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial | Nature Medicine https://t.co/1T2qbCxmJx

Mar 31, 2022 · 1 like · 1 share · 562 followers View post →
Mathias Hohl
@hohl_mathias · X

RT @gunnar_heine: Renale &  kardiale Wirkungen von SGLT 2 Inhibitoren (Prof. Vallon, San D... https://t.co/UI4E2aRGpq via @YouTube Heute 19…

Mar 26, 2022 · 3 shares · 274 followers View post →
marcus_saemann
@MarcusSaemann · X

RT @gunnar_heine: Renale &  kardiale Wirkungen von SGLT 2 Inhibitoren (Prof. Vallon, San D... https://t.co/UI4E2aRGpq via @YouTube Heute 19…

Mar 25, 2022 · 3 shares · 678 followers View post →
Jan Gerrit Heine
@jangerritheine · X

RT @gunnar_heine: Renale &  kardiale Wirkungen von SGLT 2 Inhibitoren (Prof. Vallon, San D... https://t.co/UI4E2aRGpq via @YouTube Heute 19…

Mar 25, 2022 · 3 shares · 14 followers View post →
Gunnar Henrik Heine
@gunnar_heine · X

Renale &  kardiale Wirkungen von SGLT 2 Inhibitoren (Prof. Vallon, San D... https://t.co/UI4E2aRGpq via @YouTube Heute 19:30 Frühlingserwachen in der Nephrologie mit Professor Vallon @MarcusSaemann @StephanSchirme1 @oegnephro @anjascheuer

Mar 25, 2022 · 4 likes · 3 shares · 2,334 followers View post →
Gunnar Henrik Heine
@gunnar_heine · X

https://t.co/UI4E2aRGpq

Mar 22, 2022 · 2,334 followers View post →
猫になりたい薬剤師
@Vannyamoto · X

https://t.co/QD8dh1w54y The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial

Mar 18, 2022 · 1,043 followers View post →
ZagasYum
@zagasyum18 · X

RT @Dr_Manito: Just published the EMPULSE trial: The SGLT2 inhibitor empagliflozin, in patients hospitalized for acute heart failure (AHF)…

Mar 17, 2022 · 23 shares · 212 followers View post →
louise clayton
@louisec_heart · X

RT @AAlMohammad87: One feels the population recruited into #Empulse trial mirrored the real life patients with #Acute_HF as 66.8% were #dec…

Mar 12, 2022 · 1 share · 651 followers View post →
Abdallah Al-Mohammad
@AAlMohammad87 · X

One feels the population recruited into #Empulse trial mirrored the real life patients with #Acute_HF as 66.8% were #decompensated_CHF and 33.2% were #Denovo @NatureMedicine @BSHeartFailure #CardioTwitter @SheffieldHosp https://t.co/lWQYf8rXxS

Mar 12, 2022 · 1 share · 924 followers View post →
Abdallah Al-Mohammad
@AAlMohammad87 · X

#Empulse in #Acute_HF #Empagliflozin was effective irrespective of #LVEF but mean #LVEF: 31% and 32% in the treatment and placebo arms, respectively #LVEF was >40% in 28.7% and 35.1% of these respective arms @NatureMedicine @BSHeartFailure #CardioTwitter https://t.co/lWQYf8rXxS

Mar 12, 2022 · 1 like · 924 followers View post →
Abdallah Al-Mohammad
@AAlMohammad87 · X

The group of @AdriaanVoors used interesting complex statistical management of the data of #Empulse trial providing the #Win_ratio where a patient is compared with every patient in the comparator group @NatureMedicine @BSHeartFailure #CardioTwitter https://t.co/lWQYf8rXxS

Mar 12, 2022 · 924 followers View post →
Abdallah Al-Mohammad
@AAlMohammad87 · X

.@AdriaanVoors published #Empulse trial: #Empagliflozin in treating #Acute_HF irrespective of #LVEF, reduced the combined end point of all cause mortality+HF events+time to first HF event/or improved KCCQ @NatureMedicine @BSHeartFailure #CardioTwitter https://t.co/lWQYf8rXxS

Mar 12, 2022 · 1 like · 924 followers View post →
Hilario Badiola
@hilariobad59 · X

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial https://t.co/ud7HRTfnZw (2/2)

Mar 12, 2022 · 187 followers View post →
flor
@flor46533196 · X

RT @JonathanNefro: Iniciar iSGLT2 durante la hospitalización de falla cardíaca agudizada, fue seguro e inclusive ofreció mejoría clínica ⇧3…

Mar 9, 2022 · 54 shares · 59 followers View post →
Petra Kienesberger, PhD
@PKienesberger · X

RT @ketonemics: The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial https…

Mar 8, 2022 · 2 shares · 501 followers View post →
Dr. Helen E. Collins
@DrHelenECollin1 · X

RT @ketonemics: The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial https…

Mar 7, 2022 · 2 shares · 2,194 followers View post →
Peter Crawford
@ketonemics · X

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial https://t.co/0wc66CNnhq The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial https://t.co/UgO730x94R

Mar 7, 2022 · 4 likes · 2 shares · 1,690 followers View post →
WelshHFNF
@WelshHFNF · X

RT @BSHeartFailure: EMPULSE published: in patients hospitalised for HF, empagliflozin reduces endpoint of death, number of HF events and ti…

Mar 6, 2022 · 12 shares · 625 followers View post →
Mohamed Eid
@Mohamedmagdieid · X

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial | Nature Medicine https://t.co/khrSitKzuw

Mar 5, 2022 · 1,885 followers View post →
Hunter Patton
@PattonPharmD · X

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial | Nature Medicine https://t.co/EJX4C55FiG

Mar 4, 2022 · 1 like · 44 followers View post →
Marie H Donnelly #25in25 #freedomfromfailure
@MarieHDonnelly1 · X

RT @BSHeartFailure: EMPULSE published: in patients hospitalised for HF, empagliflozin reduces endpoint of death, number of HF events and ti…

Mar 4, 2022 · 12 shares · 75 followers View post →
Kavita Oberoi OBE
@Kavita_Oberoi · X

RT @BSHeartFailure: EMPULSE published: in patients hospitalised for HF, empagliflozin reduces endpoint of death, number of HF events and ti…

Mar 4, 2022 · 12 shares · 4,719 followers View post →
EQE Health
@EqeSteve · X

RT @BSHeartFailure: EMPULSE published: in patients hospitalised for HF, empagliflozin reduces endpoint of death, number of HF events and ti…

Mar 4, 2022 · 12 shares · 205 followers View post →
British Adult Congenital Cardiac Nurse Association
@theBACCNA · X

RT @BSHeartFailure: EMPULSE published: in patients hospitalised for HF, empagliflozin reduces endpoint of death, number of HF events and ti…

Mar 4, 2022 · 12 shares · 1,337 followers View post →
BSH Nurse Forum
@BSHNurseForum · X

RT @BSHeartFailure: EMPULSE published: in patients hospitalised for HF, empagliflozin reduces endpoint of death, number of HF events and ti…

Mar 4, 2022 · 12 shares · 3,154 followers View post →
Dominique Auger
@DominiqueAuger1 · X

RT @BSHeartFailure: EMPULSE published: in patients hospitalised for HF, empagliflozin reduces endpoint of death, number of HF events and ti…

Mar 4, 2022 · 12 shares · 227 followers View post →
Chih
@ChihWong · X

RT @BSHeartFailure: EMPULSE published: in patients hospitalised for HF, empagliflozin reduces endpoint of death, number of HF events and ti…

Mar 3, 2022 · 12 shares · 459 followers View post →
Roberto Gutiérrez
@DrRobertoGuti · X

RT @JonathanNefro: Iniciar iSGLT2 durante la hospitalización de falla cardíaca agudizada, fue seguro e inclusive ofreció mejoría clínica ⇧3…

Mar 3, 2022 · 54 shares · 782 followers View post →
EVA
@EVA24368717 · X

RT @JonathanNefro: Iniciar iSGLT2 durante la hospitalización de falla cardíaca agudizada, fue seguro e inclusive ofreció mejoría clínica ⇧3…

Mar 3, 2022 · 54 shares · 40 followers View post →
Paul Cacciottolo
@pawlu · X

RT @BSHeartFailure: EMPULSE published: in patients hospitalised for HF, empagliflozin reduces endpoint of death, number of HF events and ti…

Mar 3, 2022 · 12 shares · 751 followers View post →
AlJuhara Thaar AlMarzoog
@AljuharaThaar · X

RT @BSHeartFailure: EMPULSE published: in patients hospitalised for HF, empagliflozin reduces endpoint of death, number of HF events and ti…

Mar 3, 2022 · 12 shares · 144 followers View post →
MedEd Global Solutions
@global_meded · X

RT @BSHeartFailure: EMPULSE published: in patients hospitalised for HF, empagliflozin reduces endpoint of death, number of HF events and ti…

Mar 3, 2022 · 12 shares · 244 followers View post →
Maggie Simpson
@m4ggiesimpson · X

RT @BSHeartFailure: EMPULSE published: in patients hospitalised for HF, empagliflozin reduces endpoint of death, number of HF events and ti…

Mar 3, 2022 · 12 shares · 4,386 followers View post →
LibKey
@libkey_io · X

@BSHeartFailure Access the paywalled article from your library: https://t.co/Q2YEsAm4kP Promote scholarly access to content by simply adding https://t.co/SXSePSX5De to the DOI URL

Mar 3, 2022 · 556 followers View post →
British Society for Heart Failure #theFword
@BSHeartFailure · X

EMPULSE published: in patients hospitalised for HF, empagliflozin reduces endpoint of death, number of HF events and time to first HF event, or a ≥5 point change KCCW at 90 days (win ratio 1.36). Nat Med 2022 https://t.co/NHP1hdgdwi

Mar 3, 2022 · 18 likes · 12 shares · 11,451 followers View post →
Carolina Reynoso
@carogr91 · X

RT @AdriaanVoors: The EMPULSE main paper is now published online! EMPULSE shows a clinical benefit of the SGLT2 inhibitor empagliflozin in…

Mar 2, 2022 · 134 shares · 117 followers View post →
Isaac González
@IsaacJGC4 · X

RT @JonathanNefro: Iniciar iSGLT2 durante la hospitalización de falla cardíaca agudizada, fue seguro e inclusive ofreció mejoría clínica ⇧3…

Mar 2, 2022 · 54 shares · 134 followers View post →
Chanchal Chandramouli
@chanchal5688 · X

RT @AdriaanVoors: The EMPULSE main paper is now published online! EMPULSE shows a clinical benefit of the SGLT2 inhibitor empagliflozin in…

Mar 2, 2022 · 134 shares · 101 followers View post →
Steven Tellez
@steventellez · X

RT @JonathanNefro: Iniciar iSGLT2 durante la hospitalización de falla cardíaca agudizada, fue seguro e inclusive ofreció mejoría clínica ⇧3…

Mar 2, 2022 · 54 shares · 18 followers View post →
jose luis taborda
@JoseLT14 · X

RT @Dr_Manito: Just published the EMPULSE trial: The SGLT2 inhibitor empagliflozin, in patients hospitalized for acute heart failure (AHF)…

Mar 2, 2022 · 23 shares · 131 followers View post →
Beatriz Díaz Molina
@Beadimo · X

RT @AdriaanVoors: The EMPULSE main paper is now published online! EMPULSE shows a clinical benefit of the SGLT2 inhibitor empagliflozin in…

Mar 2, 2022 · 134 shares · 793 followers View post →
@Anaceci.22
@AnaceciGg · X

RT @JonathanNefro: Iniciar iSGLT2 durante la hospitalización de falla cardíaca agudizada, fue seguro e inclusive ofreció mejoría clínica ⇧3…

Mar 2, 2022 · 54 shares · 184 followers View post →
Mario Alamilla-Sánchez
@MarioAlamilla · X

RT @JonathanNefro: Iniciar iSGLT2 durante la hospitalización de falla cardíaca agudizada, fue seguro e inclusive ofreció mejoría clínica ⇧3…

Mar 2, 2022 · 54 shares · 1,017 followers View post →
José Pérez Silvestre
@jopesilver · X

RT @AdriaanVoors: The EMPULSE main paper is now published online! EMPULSE shows a clinical benefit of the SGLT2 inhibitor empagliflozin in…

Mar 2, 2022 · 134 shares · 832 followers View post →
José Pérez Silvestre
@jopesilver · X

RT @FormigaFrancesc: GREAT: The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized…

Mar 2, 2022 · 3 shares · 832 followers View post →
Gabriel Tiller, MD
@Gabriel_Tiller · X

RT @JonathanNefro: Iniciar iSGLT2 durante la hospitalización de falla cardíaca agudizada, fue seguro e inclusive ofreció mejoría clínica ⇧3…

Mar 2, 2022 · 54 shares · 575 followers View post →
Dr. Hugo Corrales - Endocrinología.
@hugoendocrino · X

RT @JonathanNefro: Iniciar iSGLT2 durante la hospitalización de falla cardíaca agudizada, fue seguro e inclusive ofreció mejoría clínica ⇧3…

Mar 2, 2022 · 54 shares · 6,470 followers View post →
Dra SIR
@Dra_SIR18 · X

RT @JonathanNefro: Iniciar iSGLT2 durante la hospitalización de falla cardíaca agudizada, fue seguro e inclusive ofreció mejoría clínica ⇧3…

Mar 2, 2022 · 54 shares · 254 followers View post →
Beatriz Fernandez Fernandez
@beaff26 · X

RT @AdriaanVoors: The EMPULSE main paper is now published online! EMPULSE shows a clinical benefit of the SGLT2 inhibitor empagliflozin in…

Mar 2, 2022 · 134 shares · 2,307 followers View post →
Sowil Jr.
@wilsonjhc · X

RT @JonathanNefro: Iniciar iSGLT2 durante la hospitalización de falla cardíaca agudizada, fue seguro e inclusive ofreció mejoría clínica ⇧3…

Mar 2, 2022 · 54 shares · 258 followers View post →
Ángel Ochoa
@angelochoamed · X

RT @JonathanNefro: Iniciar iSGLT2 durante la hospitalización de falla cardíaca agudizada, fue seguro e inclusive ofreció mejoría clínica ⇧3…

Mar 2, 2022 · 54 shares · 82 followers View post →
Dario Rodriguez
@gatoso1987 · X

RT @JonathanNefro: Iniciar iSGLT2 durante la hospitalización de falla cardíaca agudizada, fue seguro e inclusive ofreció mejoría clínica ⇧3…

Mar 2, 2022 · 54 shares · 119 followers View post →
lucero
@lucymatsu · X

RT @JonathanNefro: Iniciar iSGLT2 durante la hospitalización de falla cardíaca agudizada, fue seguro e inclusive ofreció mejoría clínica ⇧3…

Mar 2, 2022 · 54 shares · 153 followers View post →
Alan G. Soriano
@GS_alanMX · X

RT @JonathanNefro: Iniciar iSGLT2 durante la hospitalización de falla cardíaca agudizada, fue seguro e inclusive ofreció mejoría clínica ⇧3…

Mar 1, 2022 · 54 shares · 566 followers View post →
Gabriela Sánchez E.
@gsestanga · X

RT @JonathanNefro: Iniciar iSGLT2 durante la hospitalización de falla cardíaca agudizada, fue seguro e inclusive ofreció mejoría clínica ⇧3…

Mar 1, 2022 · 54 shares · 1,482 followers View post →
Diorelis Mujica
@DiorelisMujica · X

RT @JonathanNefro: Iniciar iSGLT2 durante la hospitalización de falla cardíaca agudizada, fue seguro e inclusive ofreció mejoría clínica ⇧3…

Mar 1, 2022 · 54 shares · 34 followers View post →
Dani_lp
@LuzmilaDanila · X

RT @JonathanNefro: Iniciar iSGLT2 durante la hospitalización de falla cardíaca agudizada, fue seguro e inclusive ofreció mejoría clínica ⇧3…

Mar 1, 2022 · 54 shares · 76 followers View post →
Ricardo Orozco C.
@Dr_Orozco_Nefro · X

RT @JonathanNefro: Iniciar iSGLT2 durante la hospitalización de falla cardíaca agudizada, fue seguro e inclusive ofreció mejoría clínica ⇧3…

Mar 1, 2022 · 54 shares · 1,378 followers View post →
Danni
@gearstton · X

RT @JonathanNefro: Iniciar iSGLT2 durante la hospitalización de falla cardíaca agudizada, fue seguro e inclusive ofreció mejoría clínica ⇧3…

Mar 1, 2022 · 54 shares · 439 followers View post →
Brugada
@qt_largo · X

RT @JonathanNefro: Iniciar iSGLT2 durante la hospitalización de falla cardíaca agudizada, fue seguro e inclusive ofreció mejoría clínica ⇧3…

Mar 1, 2022 · 54 shares · 317 followers View post →
Anace Pastor ✨️ Renalis
@anace710 · X

RT @JonathanNefro: Iniciar iSGLT2 durante la hospitalización de falla cardíaca agudizada, fue seguro e inclusive ofreció mejoría clínica ⇧3…

Mar 1, 2022 · 54 shares · 1,901 followers View post →
Hb 2g/dL
@PerCasta · X

RT @JonathanNefro: Iniciar iSGLT2 durante la hospitalización de falla cardíaca agudizada, fue seguro e inclusive ofreció mejoría clínica ⇧3…

Mar 1, 2022 · 54 shares · 486 followers View post →
Carlos Andres
@GilgameshAZ · X

RT @JonathanNefro: Iniciar iSGLT2 durante la hospitalización de falla cardíaca agudizada, fue seguro e inclusive ofreció mejoría clínica ⇧3…

Mar 1, 2022 · 54 shares · 363 followers View post →
René Rodríguez Cruz
@Rene_RodCr1703 · X

RT @Dr_Manito: Just published the EMPULSE trial: The SGLT2 inhibitor empagliflozin, in patients hospitalized for acute heart failure (AHF)…

Mar 1, 2022 · 23 shares · 62 followers View post →
DeniFlores8
@DeniFlores8 · X

RT @AdriaanVoors: The EMPULSE main paper is now published online! EMPULSE shows a clinical benefit of the SGLT2 inhibitor empagliflozin in…

Mar 1, 2022 · 134 shares · 33 followers View post →
Mifre
@Irwing26 · X

RT @JonathanNefro: Iniciar iSGLT2 durante la hospitalización de falla cardíaca agudizada, fue seguro e inclusive ofreció mejoría clínica ⇧3…

Mar 1, 2022 · 54 shares · 47 followers View post →
Jonathan MD ✡︎
@jvhernandezmd · X

RT @JonathanNefro: Iniciar iSGLT2 durante la hospitalización de falla cardíaca agudizada, fue seguro e inclusive ofreció mejoría clínica ⇧3…

Mar 1, 2022 · 54 shares · 520 followers View post →
Mayra Avilés
@marsdance21 · X

RT @JonathanNefro: Iniciar iSGLT2 durante la hospitalización de falla cardíaca agudizada, fue seguro e inclusive ofreció mejoría clínica ⇧3…

Mar 1, 2022 · 54 shares · 296 followers View post →
Carlos Andrés Regino
@regino_a · X

RT @JonathanNefro: Iniciar iSGLT2 durante la hospitalización de falla cardíaca agudizada, fue seguro e inclusive ofreció mejoría clínica ⇧3…

Mar 1, 2022 · 54 shares · 429 followers View post →
latitud0scura
@latitud0scura · X

RT @JonathanNefro: Iniciar iSGLT2 durante la hospitalización de falla cardíaca agudizada, fue seguro e inclusive ofreció mejoría clínica ⇧3…

Mar 1, 2022 · 54 shares · 145 followers View post →
Iván Mogollón
@IMogolln · X

RT @JonathanNefro: Iniciar iSGLT2 durante la hospitalización de falla cardíaca agudizada, fue seguro e inclusive ofreció mejoría clínica ⇧3…

Mar 1, 2022 · 54 shares · 136 followers View post →
Manuel Vazquez V
@ManuelVVidaurre · X

RT @JonathanNefro: Iniciar iSGLT2 durante la hospitalización de falla cardíaca agudizada, fue seguro e inclusive ofreció mejoría clínica ⇧3…

Mar 1, 2022 · 54 shares · 277 followers View post →
UMCG Cardiology Research Institute
@CardiologyUmcg · X

RT @AdriaanVoors: the EMPULSE main paper is available online here https://t.co/xwLCG4D6l8 or as a PDF here https://t.co/BvirtYZvZZ.

Mar 1, 2022 · 2 shares · 388 followers View post →
Mazhar Amirali
@mazhar_amirali · X

RT @ankiacoetzee: The SGLT2 inhibitor Empagliflozin in patients hospitalized for acute heart failure: clinical benefit in 90 days after sta…

Mar 1, 2022 · 1 share · 184 followers View post →
名前
@akkiii0830 · X

https://t.co/gu3uy4uM6C The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial

Mar 1, 2022 · 245 followers View post →
Gustavo Moreira
@gugamor11 · X

RT @JanBiegus: I am so happy to share our paper showing the clinical benefit of Empagliflozin in acute heart failure settings. EMPULSE tria…

Mar 1, 2022 · 5 shares · 34 followers View post →
Xavi Cuervo
@Xavicalero1 · X

RT @Dr_Manito: Just published the EMPULSE trial: The SGLT2 inhibitor empagliflozin, in patients hospitalized for acute heart failure (AHF)…

Mar 1, 2022 · 23 shares · 186 followers View post →
Nicolás Montúfar
@NicoMontufar11 · X

RT @Dr_Manito: Just published the EMPULSE trial: The SGLT2 inhibitor empagliflozin, in patients hospitalized for acute heart failure (AHF)…

Mar 1, 2022 · 23 shares · 449 followers View post →
Rodrigo Abad
@RodrigoAbad1917 · X

RT @jorgericof: The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial | Natu…

Mar 1, 2022 · 5 shares · 2,256 followers View post →
Guillermo Rodríguez
@Guillermo_henle · X

https://t.co/nebReXnoyq

Mar 1, 2022 · 1,450 followers View post →
Brugada
@qt_largo · X

RT @Dr_Manito: Just published the EMPULSE trial: The SGLT2 inhibitor empagliflozin, in patients hospitalized for acute heart failure (AHF)…

Mar 1, 2022 · 23 shares · 317 followers View post →
Alvaro DaSilva
@Daalal_5 · X

RT @jorgericof: The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial | Natu…

Mar 1, 2022 · 5 shares · 194 followers View post →
ankia coetzee
@ankiacoetzee · X

The SGLT2 inhibitor Empagliflozin in patients hospitalized for acute heart failure: clinical benefit in 90 days after starting treatment. @NatureMedicine #Empagliflozin #Empulse trial https://t.co/RjLhJBco9P

Feb 28, 2022 · 3 likes · 1 share · 1,740 followers View post →
Anamaria Cl. Pharmacology
@ClPharmacology · X

RT @Dr_Manito: Just published the EMPULSE trial: The SGLT2 inhibitor empagliflozin, in patients hospitalized for acute heart failure (AHF)…

Feb 28, 2022 · 23 shares · 66 followers View post →
Raul Villar
@DrRaulvillar · X

RT @Dr_Manito: Just published the EMPULSE trial: The SGLT2 inhibitor empagliflozin, in patients hospitalized for acute heart failure (AHF)…

Feb 28, 2022 · 23 shares · 409 followers View post →
Raul Villar
@DrRaulvillar · X

RT @FormigaFrancesc: GREAT: The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized…

Feb 28, 2022 · 3 shares · 409 followers View post →
Javier Cornejo Martín
@cornejo_79 · X

RT @Dr_Manito: Just published the EMPULSE trial: The SGLT2 inhibitor empagliflozin, in patients hospitalized for acute heart failure (AHF)…

Feb 28, 2022 · 23 shares · 695 followers View post →
Matthew Kahn
@cardiologyMCR · X

RT @JanBiegus: I am so happy to share our paper showing the clinical benefit of Empagliflozin in acute heart failure settings. EMPULSE tria…

Feb 28, 2022 · 5 shares · 863 followers View post →
| Daniel Sierra LM |
@DanielSierraLM · X

RT @Dr_Manito: Just published the EMPULSE trial: The SGLT2 inhibitor empagliflozin, in patients hospitalized for acute heart failure (AHF)…

Feb 28, 2022 · 23 shares · 2,496 followers View post →
Rachna Kataria, MD
@rachkataria · X

RT @JanBiegus: I am so happy to share our paper showing the clinical benefit of Empagliflozin in acute heart failure settings. EMPULSE tria…

Feb 28, 2022 · 5 shares · 3,605 followers View post →
Marat Fudim, MD MHS
@FudimMarat · X

RT @JanBiegus: I am so happy to share our paper showing the clinical benefit of Empagliflozin in acute heart failure settings. EMPULSE tria…

Feb 28, 2022 · 5 shares · 4,512 followers View post →
Jan Biegus
@JanBiegus · X

I am so happy to share our paper showing the clinical benefit of Empagliflozin in acute heart failure settings. EMPULSE trial results. https://t.co/oQtjONfGgk https://t.co/8qzLxf7C3w

Feb 28, 2022 · 24 likes · 5 shares · 436 followers View post →
fausto heredia z.
@drfherediaz · X

RT @jorgericof: The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial | Natu…

Feb 28, 2022 · 5 shares · 4,353 followers View post →
alicia mabel gimenez
@aliciamabelgim1 · X

RT @jorgericof: The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial | Natu…

Feb 28, 2022 · 5 shares · 317 followers View post →
HUGO COLOMBO MD
@HCOLOMBO1958 · X

RT @Dr_Manito: Just published the EMPULSE trial: The SGLT2 inhibitor empagliflozin, in patients hospitalized for acute heart failure (AHF)…

Feb 28, 2022 · 23 shares · 1,122 followers View post →
Dr Jorge Rico Fontalvo. MD.FISN. FSLANH , PhD
@jorgericof · X

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial | Nature Medicine https://t.co/N6lq4z1gzT

Feb 28, 2022 · 26 likes · 5 shares · 5,113 followers View post →
Miguel Puentes Chiachío
@chiachio84 · X

RT @Dr_Manito: Just published the EMPULSE trial: The SGLT2 inhibitor empagliflozin, in patients hospitalized for acute heart failure (AHF)…

Feb 28, 2022 · 23 shares · 462 followers View post →
ErwingGurrola
@GurrolaErwing · X

RT @Dr_Manito: Just published the EMPULSE trial: The SGLT2 inhibitor empagliflozin, in patients hospitalized for acute heart failure (AHF)…

Feb 28, 2022 · 23 shares · 165 followers View post →
Mercedes Rivas-Lasarte
@m_rivaslasarte · X

RT @j_alvarezgarcia: ⚡️An Evidence-based shortcut!

Feb 28, 2022 · 1 share · 904 followers View post →
Nelson murillo
@nemurillob · X

RT @Dr_Manito: Just published the EMPULSE trial: The SGLT2 inhibitor empagliflozin, in patients hospitalized for acute heart failure (AHF)…

Feb 28, 2022 · 23 shares · 246 followers View post →
Jesús Álvarez-García
@j_alvarezgarcia · X

⚡️An Evidence-based shortcut!

Feb 28, 2022 · 5 likes · 1 share · 2,878 followers View post →
Enrique Santas
@SantasEnrique · X

RT @Dr_Manito: Just published the EMPULSE trial: The SGLT2 inhibitor empagliflozin, in patients hospitalized for acute heart failure (AHF)…

Feb 28, 2022 · 23 shares · 5,532 followers View post →
Surenjav Chimed
@surenjav_ch · X

RT @AdriaanVoors: the EMPULSE main paper is available online here https://t.co/xwLCG4D6l8 or as a PDF here https://t.co/BvirtYZvZZ.

Feb 28, 2022 · 2 shares · 205 followers View post →
Med Peds Hospitalist
@medpedshosp · X

RT @Abraham_RMI: The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial Via ⁦…

Feb 28, 2022 · 1 share · 14,206 followers View post →
Carlos Ortiz Bautista
@Carlos_Ortiz85 · X

RT @Dr_Manito: Just published the EMPULSE trial: The SGLT2 inhibitor empagliflozin, in patients hospitalized for acute heart failure (AHF)…

Feb 28, 2022 · 23 shares · 523 followers View post →
Elena García Romero
@e_garciaromero · X

RT @Dr_Manito: Just published the EMPULSE trial: The SGLT2 inhibitor empagliflozin, in patients hospitalized for acute heart failure (AHF)…

Feb 28, 2022 · 23 shares · 515 followers View post →
Abraham E. Gracia R.
@Abraham_RMI · X

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial Via ⁦@NatureMedicine⁩ CC ⁦@Hilda2787⁩ https://t.co/Dn2e37SVry

Feb 28, 2022 · 10 likes · 1 share · 4,683 followers View post →
Ernesto Guevara
@dr_guevara · X

RT @FormigaFrancesc: GREAT: The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized…

Feb 28, 2022 · 3 shares · 382 followers View post →
Francesc Formiga
@FormigaFrancesc · X

GREAT: The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial https://t.co/xNz90Jr8Ik @GiuseppeGalati_ @almucastro01 @SeguraCardio @Dr_Manito @JTLLERGO @fikkumamoto @SABOURETCardio @redGDPS @Diabetes_SEMI @dr_guevara

Feb 28, 2022 · 27 likes · 3 shares · 1,944 followers View post →
Pere Llorens
@LlorensPere · X

RT @Dr_Manito: Just published the EMPULSE trial: The SGLT2 inhibitor empagliflozin, in patients hospitalized for acute heart failure (AHF)…

Feb 28, 2022 · 23 shares · 3,626 followers View post →
Carolina Ortiz
@Carol_O_C · X

RT @Dr_Manito: Just published the EMPULSE trial: The SGLT2 inhibitor empagliflozin, in patients hospitalized for acute heart failure (AHF)…

Feb 28, 2022 · 23 shares · 2,757 followers View post →
Lucía Matute
@lucia_matute · X

RT @Dr_Manito: Just published the EMPULSE trial: The SGLT2 inhibitor empagliflozin, in patients hospitalized for acute heart failure (AHF)…

Feb 28, 2022 · 23 shares · 703 followers View post →
Fernando rius
@rius232 · X

RT @Dr_Manito: Just published the EMPULSE trial: The SGLT2 inhibitor empagliflozin, in patients hospitalized for acute heart failure (AHF)…

Feb 28, 2022 · 23 shares · 27 followers View post →
Laura Pérez
@tatana2007 · X

RT @Dr_Manito: Just published the EMPULSE trial: The SGLT2 inhibitor empagliflozin, in patients hospitalized for acute heart failure (AHF)…

Feb 28, 2022 · 23 shares · 237 followers View post →
Adriaan Voors
@AdriaanVoors · X

the EMPULSE main paper is available online here https://t.co/xwLCG4D6l8 or as a PDF here https://t.co/BvirtYZvZZ.

Feb 28, 2022 · 4 likes · 2 shares · 347 followers View post →
Alberto Esteban
@doctorchecho · X

RT @Dr_Manito: Just published the EMPULSE trial: The SGLT2 inhibitor empagliflozin, in patients hospitalized for acute heart failure (AHF)…

Feb 28, 2022 · 23 shares · 6,001 followers View post →
Nicolas Manito
@Dr_Manito · X

Just published the EMPULSE trial: The SGLT2 inhibitor empagliflozin, in patients hospitalized for acute heart failure (AHF) is well tolerated and results in significant clinical benefit in the 90 days after starting treatment. New evidence for optimization in AHF setting https://t.co/MnQNjZYbDa

Feb 28, 2022 · 75 likes · 23 shares · 5,471 followers View post →